Antea Participaties’ De Boeck discusses Dutch SME investing in Jort Kelder podcast interview
Bitget2026/10/06 13:45Antea Participaties Management’s founder and director Robert De Boeck discussed the firm’s buildout in an interview with Jort Kelder. Conversation centered on investing in Dutch SMEs, deal assessment, and working with management teams post-investment. De Boeck addressed underperforming investments, focusing on response tactics, decision-making, and lessons applied to subsequent deals. Interview closed with De Boeck outlining Antea’s future plans. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Antea Participaties Management BV published the original content used to generate this news brief on October 06, 2026, and is solely responsible for the information contained therein.
- Antea Participaties Management’s founder and director Robert De Boeck discussed the firm’s buildout in an interview with Jort Kelder.
- Conversation centered on investing in Dutch SMEs, deal assessment, and working with management teams post-investment.
- De Boeck addressed underperforming investments, focusing on response tactics, decision-making, and lessons applied to subsequent deals.
- Interview closed with De Boeck outlining Antea’s future plans.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Former BioNTech executive leads Bambusa Therapeutics (BBTX.US) in sprint to Nasdaq, "boosting" eczema drug trials
Bambusa Therapeutics Inc. has filed for an initial public offering, planning to raise funds for clinical trials of treatments for eczema and other inflammatory diseases.
JPMorgan raises AbbVie target price to $300